What Infinite Epigenetics does

Infinite Epigenetics operates an AI-epigenetics platform combining a proprietary biological foundation model called Biological Intelligence™ with one of the world's largest DNA methylation datasets (120,000+ samples, 6 trillion analyzed data points). The model reads approximately 1 million CpG sites per test from a few drops of blood or a cheek swab — a 20x improvement over the ~50 markers read by a standard blood panel — to predict disease risk years before symptoms appear, estimate biological age, and forecast drug treatment response. The platform's initial disease focus is on four chronic conditions (Type 2 Diabetes, Cardiovascular Disease, MASLD, and COPD) that affect more than 4 billion people worldwide.

The company operates through two wholly-owned subsidiaries: TruDiagnostic, a CLIA-certified clinical diagnostics platform that has processed 120,000+ epigenetic tests, secured multiple active PLA-coded diagnostics, and supported 80+ research studies and trials with pharma and academic partners; and Tally Health, a consumer longevity testing brand co-founded by Harvard Medical School professor Dr. David Sinclair that offers at-home epigenetic age testing with periodic retesting memberships. Revenue is generated through clinical test fees billed to healthcare providers and payors (TruDiagnostic), consumer test sales and subscription retesting (Tally Health), pharma and academic research partnerships (80+ active relationships, 50+ peer-reviewed publications), and potential platform licensing of the Biological Intelligence™ model.

Go-to-market combines direct-to-consumer and clinical sales with enterprise B2B motions targeting pharmaceutical companies, academic institutions, and healthcare provider networks, supported by dedicated EVP roles for Healthcare Provider Sales, Payor Solutions, and Marketing. The company has approximately 100 employees, collaborations with Harvard, Yale, Duke, Cornell, and Stanford, and additional partners including Illumina, NOVOS Labs, and L'Oréal. Founders include Matt Dawson (MD, CEO, 6x founder), Mike Mallin (MD, CSO, 35 peer-reviewed publications), and Brad Keywell (Chairman, Tempus AI board member) — collectively $20B+ in combined exits. Infinite Epigenetics is privately held with no disclosed institutional funding rounds in the source data.

Name

Infinite Epigenetics

Legal name

Infinite Epigenetics

Website

https://infiniteepigenetics.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

101–250 employees

Short description

Infinite Epigenetics operates an AI-epigenetics platform with a proprietary foundation model trained on 120,000+ DNA methylation samples, serving clinical (TruDiagnostic), consumer (Tally Health), pharma, and academic customers with disease risk prediction, biological age testing, and drug response modeling.

Ownership category

akta.pro rank

Product category

AI-Powered Epigenetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Epigenomics & Chromatin Profiling Services (HLAGANAF)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Epigenetic diagnostics
• Biological age testing
• Clinical epigenetics
• Longevity testing
• AI disease detection

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Clinical Epigenetic Diagnostic Testing (TruDiagnostic): TruDiagnostic offers commercial epigenetic diagnostic tests processed through a CLIA-certified lab. The platform has secured multiple active PLA-coded diagnostics and processes 120,000+ epigenetic tests. Revenue is generated through test fees billed to healthcare providers, payors, and patients. The company targets healthcare provider systems and insurance payors through its EVP of Payor Solutions and EVP of Healthcare Provider Sales functions.
2. Consumer Epigenetic Age and Longevity Testing (Tally Health): Tally Health, co-founded by Dr. David Sinclair, offers consumer-facing epigenetic age testing directly to individuals. Tests are available for purchase (likely one-time or subscription-based retesting) with results delivered alongside personalized lifestyle and supplement recommendations. Membership programs offer regular retesting (every six months).
3. Pharma and Academic Research Partnerships: Revenue from research partnerships with pharma companies and academic institutions, supporting drug discovery, trial enrichment, treatment response prediction, and drug target identification. 80+ research studies and trials supported. 50+ peer-reviewed publications produced with partners.
4. Platform Licensing and Data Services: Potential licensing of the Biological Intelligence™ foundation model and proprietary algorithms to pharma, biotech, and healthcare partners for applications including patient stratification, biomarker discovery, and companion diagnostics development.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Infinite Epigenetics operates an AI-epigenetics platform that reads approximately 1 million DNA methylation sites per blood or cheek swab sample using its proprietary Biological Intelligence™ foundation model trained on 120,000+ samples. The platform is commercialized through two operating companies: TruDiagnostic delivers PLA-coded clinical epigenetic diagnostic tests and disease-risk prediction for Type 2 Diabetes, Cardiovascular Disease, MASLD, and COPD to healthcare providers, payors, pharma, and academic partners; Tally Health sells consumer epigenetic age tests directly to individuals via at-home collection kits with membership-based retesting.

Product overview

Infinite Epigenetics operates as an AI-epigenetics platform comprising two operating companies: TruDiagnostic (clinical diagnostics) and Tally Health (consumer testing). The core technology is the proprietary Biological Intelligence AI foundation model, trained on 120,000+ epigenetic samples analyzing 1 million+ DNA methylation sites per test. TruDiagnostic serves clinical customers with disease detection and supports pharma/academic research partnerships, while Tally Health offers consumer-facing TallyAge epigenetic age testing using TIME-SEQ methodology. Both operating companies feed data into the shared biological AI model, creating a compounding data flywheel that improves predictive accuracy with every test. The platform targets four major chronic diseases (type 2 diabetes, cardiovascular disease, MASLD, COPD) and provides biological age/longevity assessment.

Differentiator

Problem solved

Functional benefit

Brands

• TruDiagnostic: Operating company - commercial diagnostics platform and methylation data engine for clinical care
• Tally Health
• TallyAge
• TIME-SEQ
• Biological Intelligence
• Infinite Platform

Products and services

• TruDiagnostic Clinical Epigenetic Testing

Quantifiable outcome

• Measures over 1 million epigenetic signals per test vs ~50 in standard blood panels — a 20x improvement in biological data yield from the same sample
• +8 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Harvard Medical School / Harvard ResearcherscoreStrategic or Co-development PartnerHarvard researchers including Dr. David Sinclair (Harvard Medical School professor, co-founder of Tally Health) and other Harvard-affiliated scientists collaborated on epigenetic aging clock research and publications. The OMICmAge biological age clock is a Harvard and TruDiagnostic collaboration validated in 14,000+ TruDiagnostic samples and published in Nature Aging.
• Yale UniversitycoreStrategic or Co-development PartnerYale University researchers are listed among the 80+ research partnerships supporting Infinite Epigenetics' science. Academic collaborations with Yale contribute to peer-reviewed publications and the validation of epigenetic clocks and disease risk models.
• Duke UniversitycoreStrategic or Co-development PartnerDuke University researchers and faculty are among the academic research partners contributing to Infinite Epigenetics' scientific platform. The company displays the Duke logo in its partner/research section on the main website, indicating an established research relationship.
• Cornell UniversityminorStrategic or Co-development PartnerCornell University researchers are listed among the academic partners contributing to the company's research network. The Cornell logo appears in the partner section of the Infinite Epigenetics website.
• Stanford UniversityminorStrategic or Co-development PartnerStanford University is listed as a research partner, appearing in the company's published research section. A published study on vegan diet and epigenetic aging was co-authored with Stanford researchers and published through TruDiagnostic.
• TruDiagnosticcoreStrategic or Co-development PartnerTruDiagnostic is the operating company powering clinical diagnostics. It has processed 120,000+ epigenetic tests, secured multiple PLA-coded diagnostics, and supported 80+ research studies and trials. TruDiagnostic collects clinical samples that feed into the shared Biological Intelligence™ foundation model.
• Tally HealthcoreStrategic or Co-development PartnerTally Health is the consumer operating company co-founded by Dr. David Sinclair. It offers consumer longevity and biological-age testing with 15+ peer-reviewed publications validating its science. Tally Health collects consumer epigenetic samples that also feed into the shared model.
• Pharma Companies (80+ partnerships)coreStrategic or Co-development Partner80+ research partnerships with pharmaceutical companies supporting drug discovery, trial enrichment, treatment response prediction, and biomarker validation. These partnerships leverage the platform's epigenetic data and AI model capabilities for pharma R&D applications.
• Life Science Companies (80+ partnerships)coreStrategic or Co-development PartnerLife science companies partner with Infinite Epigenetics for access to epigenetic biomarker data, proprietary algorithms, and the biological AI platform for applications including companion diagnostics and patient stratification.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Exact Sciences: Exact Sciences markets Cologuard (DNA-based colorectal cancer screening) and Oncotype DX, making it a broad incumbent in molecular diagnostics with payor relationships and commercial scale. Its DNA-only approach is positioned against Infinite Epigenetics' methylation-plus-AI platform.
• Guardant Health: Guardant Health is a liquid biopsy and molecular diagnostics company focused on oncology with established clinical sales, payor contracts, and CLIA-certified lab infrastructure. Comparable as a CLIA-certified diagnostics operator with AI-driven interpretation of complex biological signals.
• 23andMe: 23andMe is a consumer genetic testing platform with a large proprietary dataset and pharma licensing business (23andMe Therapeutics / GSK deal). Comparable as a DTC genetic-testing platform with a pharma-data-licensing monetization model, though using DNA rather than methylation.

Direct peers

• Tempus AI: Tempus AI is a molecular diagnostics and AI platform operator in clinical care, with shared DNA-methylation and multi-omic capabilities. It is a direct peer — and notably, Infinite Epigenetics' co-founder Brad Keywell was a board member at Tempus AI, indicating close competitive awareness.
• GRAIL: GRAIL develops methylation-based blood tests for early cancer detection (Galleri), directly competing in the same epigenetic-diagnostics category. It is the most direct methylation-based competitor and validates the commercial potential of population-scale epigenetic testing.
• Function Health: Function Health is a consumer-facing preventive diagnostics platform offering comprehensive blood-based health testing and longevity insights. Directly comparable as a DTC diagnostics competitor focused on proactive healthspan, similar to Tally Health.
• Human Longevity Inc. Human Longevity Inc. offers whole-genome and advanced diagnostics for longevity-focused consumers and clinicians. Comparable as a premium longevity diagnostics platform targeting healthspan, with similar use of genomics and advanced biomarkers.

Emerging players

• Fountain Life: Fountain Life operates preventive health and longevity diagnostics centers offering advanced biomarker testing and full-body imaging. Comparable as a premium longevity diagnostics brand targeting affluent health-conscious consumers.
• Deep Genomics: Deep Genomics applies AI to genomic and biological data for drug target identification and development. Comparable as an AI-biology platform company serving pharma R&D, intersecting with Infinite Epigenetics' drug-discovery and biomarker-licensing offerings.
• Elysium Health: Elysium Health is a consumer longevity company marketing science-backed supplements with biological-age testing (Index). Comparable in the consumer longevity-testing category adjacent to Tally Health, though more focused on supplements than diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Infinite Epigenetics